Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 28:13:1142081.
doi: 10.3389/fonc.2023.1142081. eCollection 2023.

Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives

Shuang Zhang  1 , Ying Cheng  1
Affiliations
Review

Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives

Shuang Zhang et al. Front Oncol. .

Abstract

Small-cell lung cancer (SCLC) is a fatal subtype of lung cancer characterized by high aggressiveness, poor prognosis, and limited treatment options. For the first time in more than three decades, it has been demonstrated that the addition of immunotherapy to chemotherapy improved the survival of patients with extensive-stage SCLC, thereby immunotherapy plus chemotherapy established a new standard of first-line treatment. However, it is important to improve the curative effect of immunotherapy on SCLC and identify the patients who could benefit from such treatment. In this article, we review the current status of the first-line immunotherapy, the strategies to improve the efficacy of immunotherapy and the discovery of potential predictive biomarkers of immunotherapy for SCLC.

Keywords: ES-SCLC; biomarker; immune checkpoint inhibitors; immunotherapy; small cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer (2017) 17(12):725–37. doi: 10.1038/nrc.2017.87 - DOI - PubMed
    1. Davis S, Stanley KE, Yesner R, Kuang DT, Morris JF. Small-cell carcinoma of the lung–survival according to histologic subtype: a veterans administration lung group study. Cancer (1981) 47(7):1863–6. doi: 10.1002/1097-0142(19810401)47:7<1863::AID-CNCR2820470724>3.0.CO;2-6 - DOI - PubMed
    1. Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, et al. . Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol (2009) 27(28):4787–92. doi: 10.1200/JCO.2009.23.1548 - DOI - PubMed
    1. Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, et al. . Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol (2012) 30(14):1692–8. doi: 10.1200/JCO.2011.40.4905 - DOI - PubMed
    1. Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. . First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med (2018) 379(23):2220–9. doi: 10.1056/NEJMoa1809064 - DOI - PubMed

LinkOut - more resources